HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Hanna Styczen 1 , Iris Nagelmeier 2 , Tim Beissbarth 3 , Manuel Nietert 3 , Kia Homayounfar 1 , Thilo Sprenger 1 , Ute Boczek 1 , Kathrin Stanek 1 , Julia Kitz 4 , Hendrik A. Wolff 5 , B. Michael Ghadimi 1 , Peter Middel 2 , Torsten Liersch 1 , Josef Rüschoff 2 , Lena-Christin Conradi 1 1 Department of General, Visceral and Pediatric Surgery, University Medical Center, Göttingen, Germany 2 Targos Molecular Pathology, Pathology Nordhessen, Kassel, Germany 3 Department of Medical Statistics, University Medical Center, Göttingen, Germany 4 Department of Pathology, University Medical Center, Göttingen, Germany 5 Department of Radiotherapy and Radiooncology, University Medical Center, Göttingen, Germany Correspondence to: Lena-Christin Conradi, e-mail: lena.conradi@med.uni-goettingen.de Keywords: colorectal cancer, HER-2, HER-3, targeted therapy, liver metastases Received: January 25, 2015 Accepted: March 09, 2015 Published: April 13, 2015 ABSTRACT Objective: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. Patients and Methods: Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies ( n = 29) or resection specimens ( n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months. Results: Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status ( p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 ( p = 0.037). Conclusions: HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesorectal excision for rectal cancer
MacFarlane, J. K., Ryall, R. D. H., & Heald, R. J. (1993) · The Lancet · doi:10.1016/0140-6736(93)90207-w · Cited by 1,781
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 1×
“[49] identified in vitro the HER-2 overexpression and gene amplification to be a negative determinant in addition to KRAS mutation for response to an antiEGFR therapy like cetuximab in metastatic CRC.”
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Eskens, F. A. L. M., Mom, C. H., Planting, A. S. T., Gietema, J. A., Amelsberg, A., Huisman, H., van Doorn, L., Burger, H., Stopfer, P., Verweij, J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604108 · Cited by 234
Welslau, M., Diéras, V., Sohn, J., Hurvitz, S. A., Lalla, D., Fang, L., Althaus, B., Guardino, E., & Miles, D. (2014) · Cancer · doi:10.1002/cncr.28465 · Cited by 126
Lédel, F., Hallström, M., Ragnhammar, P., Öhrling, K., & Edler, D. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.008 · Cited by 52 · cited 6×
“A recent publication showed a HER3 expression in about 70% of primary tumors of stage II and III CRC and in about 75% of corresponding lymph node metastases [29].”
Influential
Cited by
Cell Therapy as Target Therapy against Colon Cancer Stem Cells
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098163 · Cited by 24
HER3 Alterations in Cancer and Potential Clinical Implications
Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T. (2022) · Cancers · doi:10.3390/cancers14246174 · Cited by 21
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14
“HER2 is overexpressed in esophageal adenocarcinoma as well as in breast, gastric, lung, pancreatic, and CRCs (68,69).”
Rathore, M., Zhang, W., Wright, M., Bhattacharya, R., Fan, F., Vaziri-Gohar, A., Winter, J., Wang, Z., Markowitz, S. D., Willis, J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0633 · Cited by 14
Metadata
- Authors
- Styczen, H., Nagelmeier, I., Beissbarth, T., Nietert, M., Homayounfar, K., Sprenger, T., Boczek, U., Stanek, K., Kitz, J., Wolff, H. A., Ghadimi, B. M., Middel, P., Liersch, T., Rüschoff, J., & Conradi, L.-C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-04-13
- Volume
- 6
- Issue
- 17
- Pages
- 15065-15076
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1829134241
- Cited by
- 29
- References
- 6
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. https://app.cochat.ai/papers/10.18632/oncotarget.3527
- The paper
- Styczen, H., Nagelmeier, I., Beissbarth, T., Nietert, M., Homayounfar, K., Sprenger, T., Boczek, U., Stanek, K., Kitz, J., Wolff, H. A., Ghadimi, B. M., Middel, P., Liersch, T., Rüschoff, J., & Conradi, L.-C. (2015). HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.3527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.